@article{lin:2020a,
  Author = {Lin, Xiaolei and Ji, Yuan},
  Journal = {Journal of Biopharmaceutical Statistics},
  Number = 6,
  Pages = {993--1005},
  Title = {The Joint i3+3 (Ji3+3) design for phase I/II adoptive cell therapy clinical trials},
  Volume = 30,
  Year = 2020,
  url = {https://doi.org/10.1080/10543406.2020.1818250}
}
@article{thall:2004,
  Author = {Thall, Peter F. and Cook, John D.},
  Journal = {Biometrics},
  Number = 3,
  Pages = {684--693},
  Title = {Dose-finding based on efficacy-toxicity trade-offs},
  Volume = 60,
  Year = 2004,
  url = {https://doi.org/10.1111/j.0006-341X.2004.00218.x}
}
@book{yuan:2016,
  Author = {Yuan, Ying and Nguyen, Hoang Q. and Thall, Peter F.},
  Title = {{Bayesian} Designs for Phase I-II Clinical Trials},
  Year = 2016,
  Publisher = {Chapman and Hall/CRC},
  Address = {New York}
}
@article{riviere:2018,
  Author = {Riviere, Marie-Karelle and Yuan, Ying and Jourdan, Jacques-Henri and Dubois, Frederic and Zohar, Sarah},
  Journal = {Statistical Methods in Medical Research},
  Number = 2,
  Pages = {466--479},
  Title = {Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization},
  Volume = 27,
  Year = 2018,
  url = {https://doi.org/10.1177/0962280216631763}
}
@article{li:2020,
  Author = {Li, Pin and Liu, Rachael and Lin, Jianchang and Ji, Yuan},
  Journal = {Journal of Biopharmaceutical Statistics},
  Number = 6,
  Pages = {979--992},
  Title = {{TEPI}-2 and {UBI}: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy},
  Volume = 30,
  Year = 2020,
  url = {https://doi.org/10.1080/10543406.2020.1814802}
}
@article{lin:2021,
  Author = {Lin, Xiaolei and Ji, Yuan},
  Journal = {Statistical Methods in Medical},
  Number = 3,
  Pages = {843--856},
  Title = {Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology},
  Volume = 30,
  Year = 2021,
  url = {https://doi.org/10.1177/0962280220977009}
}
@article{lin:2020b,
  Author = {Lin, Ruitao and Zhou, Yanhong and Yan, Fangrong and Li, Daniel and Yuan, Ying},
  Journal = {JCO Precision Oncology},
  Pages = {PO.20.00257},
  Title = {{BOIN}12: {Bayesian} optimal interval phase I/II trial design for utility-based dose finding in immunotherapy and targeted therapies},
  Volume = 4,
  Year = 2020,
  url = {https://doi.org/10.1200/PO.20.00257}
}
@article{yin:2020,
  Author = {Yin, Jun and Yuan, Ying},
  Journal = {Journal of Biopharmaceutical Statistics},
  Number = 6,
  Pages = {1006--1025},
  Title = {Checkerboard: a {Bayesian} efficacy and toxicity interval design for phase I/II dose-finding trials},
  Volume = 30,
  Year = 2020,
  url = {https://doi.org/10.1080/10543406.2020.1815033}
}
@article{calabrese:2001,
  Author = {Calabrese, Edward J. and Baldwin, Linda A.},
  Journal = {Annual Review of Public Health},
  Pages = {15--33},
  Title = {U-shaped dose-responses in biology, toxicology, and public health},
  Volume = 22,
  Year = 2001,
  url = {https://doi.org/10.1146/annurev.publhealth.22.1.15}
}
@article{lorusso:2010,
  Author = {LoRusso, Patricia M. and Boerner, Scott A. and Seymour, Lesley},
  Journal = {Clinical Cancer Research},
  Number = 6,
  Pages = {1710--1718},
  Title = {An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics},
  Volume = 16,
  Year = 2010,
  url = {https://doi.org/10.1158/1078-0432.CCR-09-1993}
}
@article{reynolds:2010,
  Author = {Reynolds, Andrew R.},
  Journal = {Dose Response},
  Number = 3,
  Pages = {253--284},
  Title = {Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer},
  Volume = 8,
  Year = 2010,
  url = {https://doi.org/10.2203/dose-response.09-049.Reynolds}
}
@article{corbaux:2019,
  Author = {Corbaux, Pauline and El-Madani, Mevidette and Tod, Michel and Peron, Julien and Maillet, Denis and Lopez, Jonathan and Freyer, Gilles and You, Benoit},
  Journal = {European Journal of Cancer},
  Pages = {40--46},
  Title = {Clinical efficacy of the optimal biological dose in earlyphase trials of anti-cancer targeted therapies},
  Volume = 120,
  Year = 2019,
  url = {https://doi.org/10.1016/j.ejca.2019.08.002}
}
@article{fraisse:2021,
  Author = {Fraisse, Julien and Dinart, Derek and Tosi, Diego and Bellera, Carine and Mollevi, Caroline},
  Journal = {BMC Cancer},
  Number = 60,
  Title = {Optimal biological dose: a systematic review in cancer phase I clinical trials},
  Volume = 21,
  Year = 2021,
  url = {https://doi.org/10.1186/s12885-021-07782-z}
}
@article{postel:2009,
  Author = {Postel-Vinay, Sophie and Arkenau, Hendrik-Tobias and Olmos, David and Ang, Joo Ern and Barriuso, Jorge and Ashley, Shukuru and Banerji, Udoyan and De-Bono, Johann and Judson, Ian and Kaye, Stanley},
  Journal = {British Journal of Cancer},
  Pages = {1373--1378},
  Number = 9,
  Title = {Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?},
  Volume = 100,
  Year = 2009,
  url = {https://doi.org/10.1038/sj.bjc.6605030}
}
@article{weber:2015,
  Author = {Weber, Jeffrey S. and Yang, James C. and Atkins, Michael B. and Disis, Mary L.},
  Journal = {Journal of Clinical Oncology},
  Pages = {2092--2099},
  Number = 18,
  Title = {Toxicities of immunotherapy for the practitioner},
  Volume = 33,
  Year = 2015,
  url = {https://doi.org/10.1200/JCO.2014.60.0379}
}
@article{penel:2011,
  Author = {Penel, Nicolas and Adenis, Antoine and Clisant, Stephanie and Bonneterre, Jacques},
  Journal = {Investigational New Drugs},
  Pages = {1414--1419},
  Number = 6,
  Title = {Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs},
  Volume = 29,
  Year = 2011,
  url = {https://doi.org/10.1007/s10637-010-9490-7}
}
@article{takeda:2018,
  Author = {Takeda, Kentaro and Taguri, Masataka and Morita, Satoshi},
  Journal = {Pharmaceutical Statistics},
  Number = 4,
  Pages = {383--395},
  Title = {{BOIN-ET}: {Bayesian} optimal interval design for dose finding based on both efficacy and toxicity outcomes},
  Volume = 17,
  Year = 2018,
  url = {https://doi.org/10.1002/pst.1864}
}
@article{takeda:2020,
  Author = {Takeda, Kentaro and Morita, Satoshi and Taguri, Masataka},
  Journal = {Pharmaceutical Statistics},
  Number = 3,
  Pages = {335--349},
  Title = {{TITE-BOIN-ET}: Time-to-event {Bayesian} optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes},
  Volume = 19,
  Year = 2020,
  url = {https://doi.org/10.1002/pst.1995}
}
@article{takeda:2022a,
  Author = {Takeda, Kentaro and Xia, Qing and Liu, Shufang and Rong, Alan},
  Journal = {Pharmaceutical Statistics},
  Number = 2,
  Pages = {496--506},
  Title = {{TITE-}g{BOIN}: Time-to-event {Bayesian} optimal interval design to accelerate dose-finding accounting for toxicity grades},
  Volume = 21,
  Year = 2022,
  url = {https://doi.org/10.1002/pst.2182}
}
@article{takeda:2022b,
  Author = {Takeda, Kentaro and Morita, Satoshi and Taguri, Masataka},
  Journal = {Biometrical Journal},
  Number = 7,
  Pages = {1178--1191},
  Title = {g{BOIN-ET}: The generalized {Bayesian} optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials},
  Volume = 64,
  Year = 2022,
  url = {https://doi.org/10.1002/bimj.202100263}
}
@article{takeda:2023,
  Author = {Takeda, Kentaro and Yamaguchi, Yusuke and Taguri, Masataka and Morita, Satoshi},
  Journal = {Biometrical Journal},
  Number = 7,
  Pages = {e2200265},
  Title = {{TITE-}g{BOIN-ET}: Time-to-event generalized {Bayesian} optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes},
  Volume = 64,
  Year = 2023,
  url = {https://doi.org/10.1002/bimj.202200265}
}
@article{yamaguchi:2024,
  Author = {Yamaguchi, Yusuke and Takeda, Kentaro and Yoshida, Satoshi and Maruo, Kazushi},
  Journal = {Journal of Biopharmaceutical Statistics},
  Number = 3,
  Pages = {379--393},
  Title = {Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study},
  Volume = 34,
  Year = 2024,
  url = {https://doi.org/10.1080/10543406.2023.2202259}
}
@article{yuan:2019,
  Author = {Yuan, Ying and Lee, J. Jack and Hilsenbeck, Susan G.},
  Journal = {JCO Precision Oncology},
  Pages = {PO.19.00032},
  Title = {Model-assisted designs for early-phase clinical trials: simplicity meets superiority},
  Volume = 3,
  Year = 2019,
  url = {https://ascopubs.org/doi/10.1200/PO.19.00032}
}
@article{yuan:2007,
  Author = {Yuan, Ying and Chappell, Richard and Bailey, Howard},
  Journal = {Biometrics},
  Number = 1,
  Pages = {173--179},
  Title = {The continual reassessment method for multiple toxicity grades: a {Bayesian} quasi-likelihood approach},
  Volume = 63,
  Year = 2007,
  url = {https://doi.org/10.1111/j.1541-0420.2006.00666.x}
}
@article{bril:1984,
  Author = {Bril, Gordon and Dykstra, Richard and Pillers, Carolyn and Robertson, Tim},
  Journal = {Journal of the Royal Statistical Society: Series C (Applied Statistics)},
  Number = 3,
  Pages = {352--357},
  Title = {Isotonic regression in two independent variables},
  Volume = 33,
  Year = 1984,
  url = {https://doi.org/10.2307/2347723}
}
@article{lin:2017,
  Author = {Lin, Ruitao and Yin, Guosheng},
  Journal = {Statistics in Medicine},
  Number = 26,
  Pages = {4106--4120},
  Title = {{STEIN}: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials},
  Volume = 36,
  Year = 2017,
  url = {https://doi.org/10.1002/sim.7428}
}
@article{zhou:2019,
  Author = {Zhou, Yanhong and Lee, J. Jack and Yuan, Ying},
  Journal = {Statistics in Medicine},
  Number = 28,
  Pages = {5299--5316},
  Title = {A utility-based {Bayesian} optimal interval ({U-BOIN}) phase I/II design to identify the optimal biological dose for targeted and immune therapies},
  Volume = 38,
  Year = 2019,
  url = {https://doi.org/10.1002/sim.8361}
}
@manual{yamaguchi:2025,
  title = {boinet: Conduct Simulation Study of {Bayesian} Optimal Interval Design with {BOIN-ET} Family},
  author = {Yamaguchi, Yusuke and Takeda, Kentaro},
  year = {2025},
  note = {{R} package version 1.3.0},
  url = {https://CRAN.R-project.org/package=boinet}
}
@book{barlow:1972,
  Author = {Barlow, R. E. and Bartholomew, D. J.  and Bremner, J. M. and Brunk, H. D.},
  Title = {Statistical Inference under Order Restrictions: The Theory and Application of Isotonic Regression},
  Year = 1972,
  Publisher = {Wiley},
  Address = {London}
}
@article{lin:2020c,
  Author = {Lin, Ruitao and Yuan, Ying},
  Journal = {Biostatistics},
  Number = 4,
  Pages = {807--824},
  Title = {Time-to-event model-assisted designs for dose-finding trials with delayed toxicity},
  Volume = 21,
  Year = 2020,
  url = {https://doi.org/10.1093/biostatistics/kxz007}
}
@manual{xiaomeng:2025,
  title = {Keyboard: {Bayesian} Designs for Early Phase Clinical Trials},
  author = {Yuan, Xiaomeng and Li, Chen and Sun, Hongying and Tang, Li and Pan, Haitao},
  year = {2025},
  note = {{R} package version 0.1.3},
  url = {https://CRAN.R-project.org/package=Keyboard}
}
@manual{kristian:2024,
  title = {escalation: A Modular Approach to Dose-Finding Clinical Trials},
  author = {Brock, Kristian and Slade, Daniel and Sweeting, Michael},
  year = {2024},
  note = {{R} package version 0.1.10},
  url = {https://CRAN.R-project.org/package=escalation}
}
@article{ades:2024,
  Author = {Ades, Lionel and Cluzeau, Thomas and Comont, Thibault and Aguinaga, Lorea and Stamatoullas, Aspasia and Meunier, Mathieu and Gyan, Emmanuel and Garnier, Alice and D'Aveni, Maud and Thepot, Sylvain and Sebert, Marie and Moldovan, Marius and Petrich, Anouk Walter and Lemarie, Karine and Chermat, Fatiha and Fontenay, Michaela and Chevret, Sylvie and Fenaux, Pierre},
  Journal = {blood},
  Pages = {351--352},
  Title = {Combining {ESA} and {Luspatercept} in non-{RS} {MDS} patients having failed {ESA} - results of the Phase 1-2 part a of the {GFM} combola study},
  Volume = 144,
  Year = 2024,
  url = {https://doi.org/10.1182/blood-2024-204791}
}
